Vima Therapeutics’ lead program, VIM0423, targets muscarinic cholinergic receptors linked to dystonia and other movement disorders.

Vima Therapeutics shares progress and milestones in press releases and media coverage.

Vima Therapeutics develops VIM0423, an oral therapy targeting the underlying cause of dystonia, currently in a phase 2 study with FDA Fast Track designation.

Vima Therapeutics believes now is the time to advance new treatments that target the root cause of movement disorders and are designed to be impactful for patients with dystonia and related movement disorders.

Vima Therapeutics combines expertise in movement disorders to develop a first-in-class oral medicine for patients with movement disorders.

Vima Therapeutics offers information on VIM0423, an oral therapy for dystonia, and its clinical study in isolated dystonia.

Vima Therapeutics is advancing a new era in treatment to help people living with movement disorders regain the freedom to move.

Vima Therapeutics presents new research findings at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. The company highlights advancements in potential treatments for neurodegenerative conditions. Attendees explore novel therapeutic approaches targeting Parkinson’s and related disorders.

Oct 2026GlobeNewswireNews article

Vima Therapeutics secures a **$100 million Series A extension** to develop **VIM0423**, an investigational oral treatment targeting **Parkinson’s disease and dystonia**. The funding supports clinical progress for the experimental therapy, which remains in investigational stages.

Mar 2026Pharmaceutical TechnologyNews article

Vima Therapeutics doses the first patient in its Phase 2 clinical trial for dystonia, testing a potential first-in-class oral therapy. The company also secures an extension of its Series A funding round to $100 million to advance development for dystonia and Parkinson’s disease. The therapy targets movement disorders with an oral administration approach, distinguishing it from existing treatments.

Mar 2026GlobeNewswireNews article

Vima, a biotech startup incubated by Atlas Venture, secures $100 million in financing to advance an oral medication targeting dystonia and Parkinson’s disease. The company aims to help patients regain voluntary movement control through its daily pill formulation. Clinical progress and regulatory milestones remain unspecified in the announcement.

Mar 2026BioPharma DiveNews article